Table 3.
Summary of results of clinical analysis of human samples
| MAP | Anti-MAP IgG | |
|---|---|---|
| T1DM |
3/10 (30%) |
5/10 (50%) |
| T2DM |
1/2 (50%) |
1/2 (50%) |
| CONTROL | 3/6 (50%) | 2/6 (33.33%) |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.